Skip to search formSkip to main contentSkip to account menu

iralukast

Known as: 1-hydroxy-1-(3-trifluoromethylphenyl)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)deca-3(E),5(Z)-diene-2-yl-7-thio-4-oxo-4H-1-benzopyran-2-carboxylic acid 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Benzopyrans

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Interaction between adenosine and allergen or compound 48/80 on lung parenchymal strips from actively sensitized Brown Norway rats.
2004
2004
Airway hyperresponsiveness to bradykinin induced by allergen challenge in actively sensitised Brown Norway rats
The mechanism(s) of bradykinin-induced bronchoconstriction was investigated in the Brown Norway (BN) rat model of allergic asthma… 
2000
2000
Trace-level quantitation of iralukast in human plasma by microbore liquid chromatography/tandem mass spectrometry.
Iralukast (CGP 45715A) is a potent peptido-leukotriene antagonist that is active in various in vitro and animal models for the… 
1999
1999
Comparative effects of a glucocorticosteroid, theophylline and the peptido-leukotriene-antagonist CGP 45715A on antigen-induced early and late phase airway response and inflammatory cell influx in…
1999
1999
Binding of iralukast to serum proteins and erythrocytes: measurements using ultrafiltration and an erythrocyte partitioning method.
1999
1999
The development of iralukast: A member of the Novartis series of cysteinyl leukotriene antagonists
The development of specific antagonists of cysteinyl leukotrienes (Cys-LTs) has provided therapeutic agents for use in diseases… 
1999
1999
Evaluation of the pharmacological activity of the pure cysteinyl-leukotriene receptor antagonists CGP 45715A (iralukast) and CGP 57698 in human airways.
Cysteinyl-containing leukotrienes (cysteinyl-LTs) produce bronchoconstriction, mucus hypersecretion, and pro-inflammatory effects… 
1998
1998
Pharmacological characterization of the cysteinyl‐leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro
Cysteinyl‐leukotrienes (cysteinyl‐LTs) are important mediators in the pathogenesis of asthma. They cause bronchoconstriction… 
1998
1998
Iralukast Novartis AG.
  • A. Bramley
  • IDrugs : the investigational drugs journal
  • 1998
  • Corpus ID: 21109584
Iralukast is an LTD4 and LTE4 antagonist under development by Novartis and in phase II clinical trials as a potential treatment… 
1998
1998
Anti-inflammatory agents and allergen-induced beta2-receptor dysfunction in isolated human bronchi.
Antigen challenge causes beta2-adrenoceptor dysfunction in sensitized human bronchi (Am. J. Respir. Crit. Care Med. 1997;155:1230… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)